Karl Keegan

Karl Keegan is the current Chief Financial Officer at E Therapeutics Plc. Karl has held this position since September 2017. Prior to that, they were the Director of Corporate Development at shield therapeutics plc from January 2017 to September 2017. From September 2012 to July 2016, they were the Chief Corporate Development Officer at vectura group plc. Karl was also the Chief Financial Officer at pharming group n.v. from September 2010 to August 2012. Karl Keegan's career began at canaccord genuity group inc. where they worked from July 2003 to April 2009 as Managing Director. Karl then worked as Managing Director at Bank of America from January 2002 to January 2003 before moving to UBS as Director from January 1999 to January 2002. Karl's most recent positions prior to their current role were as Chief Financial Officer at minster pharmaceuticals from April 2009 to February 2010 and Manager at hox therapeutics from February 2010 to present.

Karl Keegan has a Master of Science from the London Business School and a Doctor of Philosophy from the University of Cambridge. Karl also has a Bachelor of Science from University College Dublin.

They are on a team with Elaine Alexander - Executive Assistant & Office Manager, Stephanie Maley - Chief People Officer, and Alan Whitmore - Chief Scientific Officer. Karl Keegan reports to Ray Barlow, Chief Executive Officer. Some individuals on their team include Jade Silavant - Finance Manager, Nadine Fairhurst-Groethe - Head of Finance.